Use of fenoldopam to prevent radiocontrast nephropathy in high‐risk patients

Publisher Website
Google Scholar
Abstract
We evaluated the ability of fenoldopam, a newly available renal vasodilator, to prevent radiocontrast nephropathy in high‐risk patients undergoing interventional diagnostic and therapeutic angiographic procedures. We reviewed the results from 46 consecutive procedures in patients with serum creatinine ≥ 1.5 mg/dL if diabetic and ≥ 1.7 mg/dL if nondiabetic. We compared our results to a previously published cohort of similarly at‐risk patients. The incidence of radiocontrast nephropathy, defined as an increase in serum creatinine of ≥ 25% at 48 hr following the procedure, was 13% in the group treated with fenoldopam, compared to an expected 38%. The percentage change in serum creatinine at 48 hr was +16% vs. +118%, respectively, in the two groups. In this preliminary experience, the use of fenoldopam in high‐risk patients appears to minimize the likelihood of radioncontrast nephropathy. Cathet Cardiovasc Intervent 2001;53:341–345.